Gilteritinib in Combination With Venetoclax and Azacitidine for AML Patients With FLT3 Mutations Ineligible for Intensive Treatment

This study is testing a three-drug combination — gilteritinib, venetoclax, and azacitidine — for people newly diagnosed with a type of blood cancer called acute myeloid leukemia (AML) who also have a specific gene mutation (FLT3) and cannot tolerate aggressive chemotherapy. **You may be eligible if...** - You have been newly diagnosed with AML with at least 20% abnormal cells in the bone marrow - Your tumor has a FLT3 gene mutation - Doctors have determined you are not a candidate for standard intensive chemotherapy - You have already received one cycle of venetoclax + azacitidine as standard care **You may NOT be eligible if...** - Your AML has returned or stopped responding to prior treatment - You have previously been treated with gilteritinib - You have cancer that has spread to the brain or spinal fluid - You have a heart rhythm condition called long QT syndrome - You are taking certain medications that affect how the body processes drugs (strong CYP3A inducers) Talk to your doctor to see if this trial is right for you.